Skip to main content

Recombinant Feline IL-18/IL-1F4 Protein

R&D Systems, part of Bio-Techne | Catalog # 5989-RM

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
5989-RM-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
5989-RM-025

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

E. coli-derived feline IL-18/IL-1F4 protein
Tyr36-Asn192, with an N-terminal Met

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

18.3 kDa

SDS-PAGE

19 kDa, reducing conditions

Activity

Measured by its ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells in the presence of TNF-alpha.
The ED50 for this effect is 0.200-5.00 μg/mL in the presence of 20 ng/mL recombinant human TNF-alpha.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 5989-RM
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 5989-RM/CF
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-18/IL-1F4

Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma delta T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases.
IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8+ T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4+ T cells and basophils (9, 10). In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma delta T cells and CD4+ T cells (11). IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature feline IL-18 shares 87% - 89% aa sequence identity with canine and porcine IL-18 and 62% - 77% with human, mouse, rat, and rhesus IL-18 (15).

References

  1. Dinarello, C.A. et al. (2013) Front. Immunol. 4:289.
  2. Smith, D.E. (2011) J. Leukoc. Biol. 89:383.
  3. Gu, Y. et al. (1997) Science 275:206.
  4. Torigoe, K. et al. (1997) J. Biol. Chem. 272:25737.
  5. Cheung, H. et al. (2005) J. Immunol. 174:5351.
  6. Novick, D. et al. (1999) Immunity 10:127.
  7. Fehniger, T.A. et al. (1999) J. Immunol. 162:4511.
  8. Yoshimoto, T. et al. (1998) J. Immunol. 161:3400.
  9. Yoshimoto, T. et al. (2000) Nat. Immunol. 1:132.
  10. Kroeger, K.M. et al. (2009) J. Leukoc. Biol. 86:769.
  11. Lalor, S.J. et al. (2011) J. Immunol. 186:5738.
  12. Li, J. et al. (2004) Cell. Immunol. 227:103.
  13. Elbim, C. et al. (2005) Clin. Diagn. Lab. Immunol. 12:436.
  14. Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.
  15. Ishizaka, T. et al. (2001) Vet. Immunol. Immunopathol. 79:209.

Long Name

Interleukin 18

Alternate Names

IGIF, IL-1F4, IL-1g, IL18

Entrez Gene IDs

3606 (Human); 16173 (Mouse); 29197 (Rat); 397057 (Porcine); 574151 (Primate)

Gene Symbol

IL18

UniProt

Additional IL-18/IL-1F4 Products

Product Documents for Recombinant Feline IL-18/IL-1F4 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Feline IL-18/IL-1F4 Protein

For research use only

Loading...
Loading...
Loading...
Loading...